Notice2025-04257
Foreign-Trade Zone (FTZ) 43, Notification of Proposed Production Activity; Pfizer, Inc.; (Pharmaceutical Intermediate Product); Kalamazoo, Michigan
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 17, 2025
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 50 (Monday, March 17, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 50 (Monday, March 17, 2025)]
[Notices]
[Pages 12294-12295]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-04257]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-15-2025]
Foreign-Trade Zone (FTZ) 43, Notification of Proposed Production
Activity; Pfizer, Inc.; (Pharmaceutical Intermediate Product);
Kalamazoo, Michigan
Pfizer, Inc. (Pfizer) submitted a notification of proposed
production activity to the FTZ Board (the Board) for its facilities in
Kalamazoo, Michigan within Subzone 43E. The notification conforming to
the requirements of the Board's regulations (15 CFR 400.22) was
received on March 10, 2025.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>. The proposed finished
product and material/component would be added to the production
authority that the Board previously approved for the operation, as
reflected on the Board's website.
The proposed finished product is phthalimido lactol (pharmaceutical
intermediate product) (duty rate--6.5%).
The proposed foreign-status material/component is 3
phthalimidopropionaldehyde (3-PPA) (duty rate--6.5%). The request
indicates that 3-PPA is subject to duties under section 1702(a)(1)(B)
of the International Emergency Economic Powers Act (section 1702) and
section 301 of the Trade Act of 1974 (section 301), depending on the
country of origin. The applicable section 1702 and section 301
decisions require subject merchandise to be admitted to FTZs in
privileged foreign status (19 CFR 146.41).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#533527291327213237367d343c25"><span class="__cf_email__" data-cfemail="e98f9d93a99d9b888d8cc78e869f">[email protected]</span></a>. The closing period for their receipt is April 28, 2025.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Diane Finver at
<a href="/cdn-cgi/l/email-protection#13577a727d763d557a7d6576615367617277763d747c65"><span class="__cf_email__" data-cfemail="b0f4d9d1ded59ef6d9dec6d5c2f0c4c2d1d4d59ed7dfc6">[email protected]</span></a>.
[[Page 12295]]
Dated: March 11, 2025.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2025-04257 Filed 3-14-25; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 17, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.